Biotech Values

[DewDiligence]

MRNA 1Q23 highlights:

https://www.accesswire.com/viewarticle.aspx?id=752877&lang=en

• First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19

• Company in negotiations for new orders for fall of 2023 in U.S., Japan, and EU, in addition to reiterating 2023 minimum sales expectations of approximately $5.0 billion from previously announced COVID-19 vaccine Advanced Purchase Agreements

• Company preparing for potential 2024 commercial launch of its investigational RSV vaccine for older adults

• Company to begin Phase 3 trial this year of mRNA-4157 [#msg-171699374], Moderna's individualized neoantigen therapy (INT) in combination with Keytruda, for melanoma

• Company preparing for six major vaccine launches from respiratory franchise (COVID-19, RSV, Flu, and combinations), with expected annual sales of $8-15 billion by 2027